Premium Nahrungsergänzungsmittel | artgerecht

KIM-1: Biomarker for Kidney Injury Explained

KIM-1 (Kidney Injury Molecule-1) is a biomarker for acute kidney injury. It is released when kidney tubule cells are damaged and enables early diagnosis of renal impairment.

Regular tips about health Regular tips about health

Things worth knowing about "KIM-1"

KIM-1 (Kidney Injury Molecule-1) is a biomarker for acute kidney injury. It is released when kidney tubule cells are damaged and enables early diagnosis of renal impairment.

What is KIM-1?

KIM-1 stands for Kidney Injury Molecule-1. It is a transmembrane protein – a protein anchored in the cell membrane – primarily expressed in the tubular cells of the kidney. Under normal conditions, KIM-1 is barely detectable in kidney tissue. However, when kidney cells are damaged, its expression is strongly upregulated and the soluble form of the protein is shed into the urine, where it serves as a sensitive biomarker for acute kidney injury (AKI).

Biological Function

KIM-1 belongs to the TIM protein family (T-Cell Immunoglobulin and Mucin Domain Proteins) and performs several important roles in the kidney:

Phagocytosis: KIM-1 expressed on damaged tubular cells enables them to engulf and clear apoptotic (dying) cells and cellular debris.
Tissue regeneration: It supports the repair and regeneration of kidney tissue following injury.
Immune modulation: KIM-1 influences inflammatory responses in the kidney and can regulate both pro-inflammatory and anti-inflammatory processes.

KIM-1 as a Biomarker

In clinical diagnostics, KIM-1 is used as an early and highly sensitive biomarker for acute kidney injury. Compared to the conventional kidney marker creatinine, urinary KIM-1 rises significantly earlier – often before standard laboratory values indicate any decline in kidney function.

Clinical Applications of KIM-1

Acute Kidney Injury (AKI): Early detection in high-risk patients, such as those undergoing surgery, receiving contrast agents, or suffering from sepsis.
Chronic Kidney Disease (CKD): KIM-1 can serve as a progression marker to monitor the course of chronic kidney disease.
Nephrotoxicity: In pharmaceutical research and clinical practice, KIM-1 is used to detect kidney-damaging effects of drugs or substances at an early stage.
Kidney transplantation: KIM-1 can be used after transplantation as a marker for rejection reactions or ischemic damage.

Diagnosis and Measurement

KIM-1 is predominantly measured in urine, as damaged tubular cells release the soluble form of the protein directly into the urinary tract. Measurement is typically performed using ELISA (Enzyme-Linked Immunosorbent Assay) or comparable immunological assays. Values are often normalized to urinary creatinine concentration to account for variations in urine dilution.

Elevated urinary KIM-1 levels may indicate the following conditions:

Acute tubular necrosis (death of kidney tubule cells)
Ischemic kidney injury (damage caused by reduced blood supply)
Toxic kidney injury (e.g., caused by medications or contrast agents)
Chronic kidney disease with active tubular damage
Renal cell carcinoma (kidney cancer)

Clinical Significance and Research

KIM-1 has grown increasingly important in recent years. International regulatory authorities such as the FDA (US Food and Drug Administration) and the EMA (European Medicines Agency) have recognized KIM-1 as a qualified safety biomarker for preclinical and clinical nephrotoxicity studies, underscoring its relevance for drug development and safety assessment.

Furthermore, KIM-1 is being intensively studied in the context of renal fibrosis research, as chronically elevated KIM-1 levels are associated with the development of scar tissue in the kidney (fibrosis), which can lead to long-term deterioration of kidney function.

References

Han, W. K. et al. - Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney International, 2002.
Bonventre, J. V. - Kidney Injury Molecule-1 (KIM-1): a urinary biomarker and much more. Nephrology Dialysis Transplantation, 2009.
European Medicines Agency (EMA) - Qualification of novel methodologies for drug development: guidance on the qualification of KIM-1 as a urinary biomarker for nephrotoxicity, 2014.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.